Tonix Pharmaceuticals Holding Corp (TNXP) financials
Tonix Pharmaceuticals Holding revenue and earnings by year
Tonix Pharmaceuticals Holding's revenue was $13.1 million in the fiscal year to December 31, 2025, up 29.8% from the year before. Net income was -$124 million, -946.2% of revenue.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 3 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Revenue | 13 | 10 | 8 |
| Revenue growth | 29.8% | 29.9% | — |
| Gross profit | 6 | 2 | 3 |
| Gross margin | 49.3% | 23.1% | 39.0% |
| Operating income | -126 | -137 | -118 |
| Operating margin | -959.1% | -1354.3% | -1523.9% |
| Net income | -124 | -130 | -117 |
| Net margin | -946.2% | -1288.3% | -1501.8% |
| Diluted EPS | -$14.57 | -$176.60 | -$14720.25 |
| Free cash flow | -103 | -61 | -109 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open TNXP in Markets.
How Tonix Pharmaceuticals Holding makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Tonmya | $11.0M | 80.9% |
| Zembrace Symtouch | $2.00M | 14.7% |
| Tosymra | $594K | 4.4% |
See also: TNXP returns
No forecast, no recommendation. This page describes Tonix Pharmaceuticals Holding Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.